The current study demonstrated that sulindac also exhibits an anticancer function within human prostate cancer cells via the promotion of cancer cell apoptosis and inhibition of cell proliferation, which was associated with the suppression of β-catenin/TCF signaling and increased JNK1 phosphorylation. The gene discussed is HNF4A; the disease is prostate carcinoma.